Kamada Ltd. Announces U.S. Proof-Of-Concept Study With Glassia® For Graft-Versus-Host Disease

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ: KMDA)(TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today a U.S.-based proof-of-concept (POC) study with Glassia® to treat graft-versus-host disease (GVHD) in cooperation with Baxter International Inc. conducted at the Fred Hutchinson Cancer Research Center in Seattle, Washington. Glassia is Kamada’s proprietary, highly-purified, liquid form of human Alpha-1 Antitrypsin (AAT) administered intravenously and Baxter currently markets the treatment in the U.S. for AAT Deficiency. Results from this POC study in GVHD may support global clinical development activities and may serve as a platform to apply for an expansion of the AAT indications to include general organ transplantation, based on a similar mechanism of action.

Help employers find you! Check out all the jobs and post your resume.